Camp4 director files initial Form 3

Camp4 Therapeutics Corp director Michael F. MacLean filed an initial Form 3, which is the required statement of beneficial ownership when someone becomes an insider.

Accepted by SEC EDGAR 04/03/2026 - 04:42 PM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Camp4 Therapeutics Corp director Michael F. MacLean filed an initial Form 3, which is the required statement of beneficial ownership when someone becomes an insider. This filing lists him as a director but does not report any buy or sell transactions in the company’s securities.

Key Terms

Form 3, beneficial ownership, reporting person

3 terms

Form 3 regulatory

"filed an initial Form 3, which is the required statement"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

beneficial ownership financial

"required statement of beneficial ownership when someone becomes an insider"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

reporting person regulatory

"The Form 3 shows that Michael F. MacLean is a reporting person as a director"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Camp4 Therapeutics (CAMP) Form 3 filing for Michael F. MacLean show?

The Form 3 shows that Michael F. MacLean is a director of Camp4 Therapeutics Corp. It is an initial beneficial ownership report and, in this case, does not list any transactions or derivative positions in CAMP securities.

Did Michael F. MacLean buy or sell CAMP shares in this Form 3?

No transactions are reported in this Form 3 for Michael F. MacLean. The transaction summary shows zero buys, zero sells, and no derivative exercises, indicating this filing serves only as an initial ownership statement, not a record of trading activity.

Does the Camp4 Therapeutics (CAMP) Form 3 disclose any derivative positions?

The Form 3 derivative section for Michael F. MacLean is empty. The derivativeSummary includes no entries and the transactionSummary reports zero derivative transactions, so no options, warrants, or similar instruments are detailed in this filing.

What is the role of Michael F. MacLean at Camp4 Therapeutics according to this filing?

According to the Form 3, Michael F. MacLean is a director of Camp4 Therapeutics Corp. The officer fields are not marked, so he is identified solely in his capacity as a director, which triggers the requirement to file this ownership statement.

Does the CAMP Form 3 mention any Rule 10b5-1 trading plans or special footnotes?

The Form 3 includes a blank footnote with no additional narrative or disclosures. There is no mention of Rule 10b5-1 trading plans or other special arrangements in the provided data for Michael F. MacLean’s initial ownership report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

MacLean Michael F

(Last) (First) (Middle)

C/O CAMP4 THERAPEUTICS CORPORATION

ONE KENDALL SQ., BLDG 1400 WEST, 3RD FL.

(Street)

CAMBRIDGE MASSACHUSETTS 02139

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
04/01/2026

3. Issuer Name and Ticker or Trading Symbol
Camp4 Therapeutics Corp [ CAMP ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Exhibit 24 - Power of Attorney

No securities are beneficially owned.

	/s/ Josh Mandel-Brehm, as Attorney-in-Fact	04/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)